Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease prospective observational multicenter study

导出原文传递

翻译打印收藏纠错

作者： Leebmann,J. ^[1] ; Roeseler,E. ^[2] ; Julius,U. ^[3] ; Heigl,F. ^[4] ; Spitthoever,R. ^[5] ; Heutling,D. ^[6] ; Breitenberger,P. ^[7] ; Maerz,W. ^[8] ; Lehmacher,W. ^[9] ; Heibges,A. ^[10] ; Klingel,R.

作者单位： Clinic for Nephrology and Dialysis, Tangermuende, Germany ^[1] Apheresis Research Institute, Stadtwaldguertel 77, 50935 Cologne, Germany ^[2] MVZ Kempten-Allgaeu, Kempten, Germany ^[3] Institute of Public Health and Preventive Medicine, University Heidelberg, Mannheim, and Synlab ^[4] Medical Clinic, University Hospital, Dresden, Germany ^[5] Medical Clinic, General Hospital, Passau, Germany ^[6] Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne ^[7] Dialysis-and Lipid Center North Rhine, Essen, Germany ^[8] KfH-Kidney Center, Germering, Germany ^[9] Center for Nephrology, Hypertension, and Metabolic Diseases, Hannover, Germany ^[10]

关键词 Blood component removal Cardiovascular diseases Coronary disease Lipoproteins Prevention & control

发布时间 2018-07-27

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交